GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirati Therapeutics Inc (NAS:MRTX) » Definitions » Other Current Assets

Mirati Therapeutics (Mirati Therapeutics) Other Current Assets : $19.36 Mil (As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Mirati Therapeutics Other Current Assets?

Mirati Therapeutics's other current assets for the quarter that ended in Sep. 2023 was $19.36 Mil.

Mirati Therapeutics's quarterly other current assets declined from Mar. 2023 ($19.25 Mil) to Jun. 2023 ($15.14 Mil) but then increased from Jun. 2023 ($15.14 Mil) to Sep. 2023 ($19.36Mil).

Mirati Therapeutics's annual other current assets increased from Dec. 2020 ($8.16 Mil) to Dec. 2021 ($11.90 Mil) increased from Dec. 2021 ($11.90 Mil) to Dec. 2022 ($15.21 Mil).


Mirati Therapeutics Other Current Assets Historical Data

The historical data trend for Mirati Therapeutics's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirati Therapeutics Other Current Assets Chart

Mirati Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.26 5.67 8.16 11.90 15.21

Mirati Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.70 15.21 19.25 15.14 19.36

Mirati Therapeutics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Mirati Therapeutics Other Current Assets Related Terms

Thank you for viewing the detailed overview of Mirati Therapeutics's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Mirati Therapeutics (Mirati Therapeutics) Business Description

Traded in Other Exchanges
Address
3545 Cray Court, San Diego, CA, USA, 92121
Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.
Executives
Jamie Christensen officer: Sr. Vice President, Chief Scie C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Benjamin Hickey officer: EVP, Chief Commercial Officer C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Aaron Ondrey officer: Interim CFO 3545 CRAY COURT, SAN DIEGO CA 92121
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Christopher Fuglesang other: See remarks 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Shehan Bharatha Dissanayake other: See remarks 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Faheem Hasnain director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John B Moriarty officer: Chief Legal Officer ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Laurie Stelzer officer: CFO 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Julie M Cherrington director 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121

Mirati Therapeutics (Mirati Therapeutics) Headlines

From GuruFocus